As many as one-third of American adults could develop diabetes in the next 40 years, according to a new analysis by the Centers for Disease Control and Prevention. The disease is also among the most expensive chronic illnesses …
Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker’s obesity drug Qnexa yesterday. Investors are hoping that the FDA’s rejection, which includes a request for more sa…
The pharmaceutical giant said its profit was impacted by a large charge related to its recent merger with Schering-Plough, but still managed to top analyst estimates. Looking forward, Merck lifted the lower end of its 2010 earn…
Pfizer’s cancer drug crizotinib was able to shrink tumors of non-small-cell lung cancer patients whose tumors carried a specific genetic mutation that fuses two genes. The early-stage study results were published in the New Eng…
Big Pharma didn’t rest Thursday, with Celgene, Sanofi-Aventis and AstraZeneca among the big names reporting earnings. A deal between Stryker and Boston Scientific and Sanofi and BMP Sunstone also made the headlines, as did some…